Revival for Antibiotics Could Spur Deals ROBERT CYRAN Merck is paying only about 4.3 times Cubist’s estimated revenue for next year — about the same multiple investors give Merck itself, making the acquisition look like a relative bargain, writes Robert Cyran of Reuters Breakingviews. December 8, 2014 at 12:00AM http://nyti.ms/1w6mwYW The New York Times Business Day Antibiotics, Drugs (Pharmaceuticals)

By ROBERT CYRAN via NYT / Eethg. Corps. Inc. / Terrence Herschel G. Business Day http://nyti.ms/1w6mwYW Revival for Antibiotics Could Spur Deals December 8, 2014 at 12:00AM The New York Times